Background illustration for clinical trials search

Paid Clinical Trials Missoula

Discover 118 paid clinical trials in Missoula, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 118

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase2, Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

for

Recurrent Non-Muscle Invasive Bladder Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Helena MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07000084

Phase3, Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06649812

Phase2, Recruiting

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

for

Head and Neck Squamous Cell Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06992427

Phase3, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for

Advanced Malignant Solid Neoplasm,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase2, Recruiting

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554406

Phase2, Recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554393

Phase2, Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT06031688

Phase2, Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04269902

Phase3, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for

Metastatic Nasopharyngeal Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06029270

Phase2, Recruiting

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for

Advanced Lung Non-Small Cell Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Helena MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03191149

Phase2, Recruiting

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

for

Castration-Resistant Prostate Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT06470243

Phase3, Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05987241

Phase2, Phase3, Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for

Pancreatic Acinar Cell Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04858334

Phase2, Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for

Mantle Cell Lymphoma

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 60+

Code: NCT05976763

Phase3, Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642572

Phase2, Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for

Breast Carcinoma, Colorectal Carcinoma,

Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,

Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18+

Code: NCT06418204

Recruiting

Paid Clinical Trials Missoula

Filter results

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Interested in new trials?

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics